C. Chen

CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study.

Q. Wang, W. Zhong, Q. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

J. Schiller, P. Bycott, C. Twelves, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel / carboplatin as fi rst-line therapy for patients with advanced non-small-cell lung cancer

J. Schiller, P. Bycott, C. Twelves, 2013 .

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

D. D. de Alwis, E. Rubin, G. Lubiniecki, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis.

S. Bae, K. Seetalarom, C. Chen, 2010 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

N. Lawrentschuk, B. Tran, I. Davis, 2022, Annals of Oncology.

Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).

R. Motzer, D. Cella, B. Rini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

R. Motzer, D. Cella, B. Rini, 2013, British Journal of Cancer.

Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC).

S. Lippman, D. Raben, E. Cohen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

32P Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)

G. Abou-Alfa, C. Chen, R. Kelley, 2020 .